NCT03185624

Effectiveness of Rifaximin on Preventing Postoperative Recurrence in Crohn's Disease

Effectiveness of Rifaximin on Preventing Postoperative Endoscopic Recurrence in Crohn's Disease Patients Without Risk Factor for Recurrence: A Multicenter Randomized Controlled Trial

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Some studies have shown that rifaximin is effective in the management of Crohn's Disease. Meanwhile, its adverse effect is tolerable. But no study has been conducted to assess its effect on preventing postoperative recurrence. Thus, we conduct a randomised controlled study to assess the effect of rifaximin on preventing postoperative endoscopic recurrence in Crohn's disease. The primary endpoint is the rate of endoscopic recurrence at 6 months.

Conditions

• Crohn Disease

Interventions

Type	Name	Description
DRUG	Rifaximin	Antibiotics

Timeline

• Start date: 2017-07-25
• Primary completion: 2018-01-31
• Completion: 2018-07-31
• First posted: 2017-06-14
• Last updated: 2017-07-19

Locations

1 site across 1 country: China